TNF and inflammatory bowel disease: Recently, Guo et al. found that high pretreatment OSM concentrations identify IBD patients at-risk of anti-TNF nonresponse at 1 year, as well as other deleterious clinical outcomes, providing further support that OSM drives intestinal inflammation and may predict response to anti-TNF therapy in patients with IBD [354].